FindTrial
Sign In

Study on in vitro methods for diagnosing drug hypersensivity

Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-14004399
Enrollment
Unknown
Registered
2014-02-10
Start date
2014-03-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug eruption

Interventions

Gold Standard:
Index test:

Sponsors

Institute of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Males and females aged 2 to 80 years; 2. To women of childbearing age, pregnancy test results must be negative; 3. Provide written informed consent and Willing and able to comply with all aspects of the protocol. If under 18 years old, informed consent will be written by the legal guardian.

Exclusion criteria

Exclusion criteria: 1. Patients with severe immune abnormalities disease and are taking immunosuppressants; 2. HIV-positive patients.

Design outcomes

Primary

MeasureTime frame
CD69;IFN-?;IL-5;T lymphocyte proliferation;—

Contacts

Public ContactBaoxi Wang

Institute of Dermatology, Chinese Academy of Medical Sciences

wangbx@ncstdlc.org+86 025-85478071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026